These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1836564)

  • 1. The efficacy of maternal age screening for Down's syndrome in Wessex.
    Youings S; Gregson N; Jacobs P
    Prenat Diagn; 1991 Jul; 11(7):419-25. PubMed ID: 1836564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of differences in the distribution of maternal age in England and Wales on the performance of prenatal screening for Down's syndrome.
    Huang T; Watt HC; Wald NJ
    Prenat Diagn; 1997 Jul; 17(7):615-21. PubMed ID: 9249861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevention of Down's syndrome in the south western region of England 1975-1985.
    Wilson N; Bickley D; McDermott A
    West Engl Med J; 1990 Mar; 105(1):15-7. PubMed ID: 2141994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal genetic services for Down's syndrome: access and provision in 1990-1991. Steering Committee of the National Confidential Enquiry into Counselling for Genetic Disorders.
    Williamson P; Harris R; Church S; Fiddler M; Rhind J
    Br J Obstet Gynaecol; 1996 Jul; 103(7):676-83. PubMed ID: 8688395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in Down's syndrome screening acceptance is predominantly observed in women aged 25-35 years.
    Gidiri M; Holding S; Lindow SW
    Womens Health (Lond); 2010 Jul; 6(4):525-9. PubMed ID: 20597617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region.
    Wellesley D; Boyle T; Barber J; Howe DT
    BMJ; 2002 Jul; 325(7354):15. PubMed ID: 12098722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
    Piggott M; Wilkinson P; Bennett J
    J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
    Crossley JA; Aitken DA; Berry E; Connor JM
    J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the disutility ratio in prenatal screening for Down's syndrome.
    van der Meulen JH; Mol BW; Pajkrt E; van Lith JM; Voorn W
    Br J Obstet Gynaecol; 1999 Feb; 106(2):108-15. PubMed ID: 10426675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prospects for "preventing" Down's syndrome in an English region.
    Forster DP
    Rev Epidemiol Sante Publique; 1980 Dec; 28(4):423-30. PubMed ID: 6452660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using decision analysis to compare policies for antenatal screening for Down's syndrome.
    Fletcher J; Hicks NR; Kay JD; Boyd PA
    BMJ; 1995 Aug; 311(7001):351-6. PubMed ID: 7640539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
    DiMaio MS; Baumgarten A; Greenstein RM; Saal HM; Mahoney MJ
    N Engl J Med; 1987 Aug; 317(6):342-6. PubMed ID: 2439909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ante-natal detection of Down's syndrome: some demographic aspects.
    Forster DP
    J Ment Defic Res; 1977 Dec; 21(4):263-72. PubMed ID: 146743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for antenatal detection of Down's syndrome.
    Wyllie JP; Madar RJ; Wright M; Burn J; Wren C
    Arch Dis Child Fetal Neonatal Ed; 1997 Jan; 76(1):F26-30. PubMed ID: 9059182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States.
    Khoshnood B; Pryde P; Blondel B; Lee KS
    Rev Epidemiol Sante Publique; 2003 Dec; 51(6):617-27. PubMed ID: 14967994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases.
    Nyberg DA; Luthy DA; Resta RG; Nyberg BC; Williams MA
    Ultrasound Obstet Gynecol; 1998 Jul; 12(1):8-14. PubMed ID: 9697277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000.
    Khoshnood B; De Vigan C; Vodovar V; Goujard J; Goffinet F
    BJOG; 2004 May; 111(5):485-90. PubMed ID: 15104615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register.
    Morris JK; Alberman E
    BMJ; 2009 Oct; 339():b3794. PubMed ID: 19858532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.